Previous studies have shown that branched-chain amino acid transferase 1 (BCAT1) is associated with tumour progression in triple-negative breast cancer (TNBC). Furthermore, CD133 has emerged as a novel cancer stem cell marker for indicating tumour progression. However, the prognostic significance of these two markers remains to be verified. This study was conducted to investigate the correlation between BCAT1 and CD133 expression and clinicopathological features, as well as the prognosis of patients with TNBC. The study cohort included 291 patients with TNBC. Tissue microarrays were constructed for both cancer and normal tissues. The expression of BCAT1 and CD133 was detected by immunohistochemical staining, and the levels were evaluated using an H-scoring system. Cut-off points for BCAT1 and CD133 expression were determined using receiver operating characteristic curves. The median follow-up time for the study participants was 68.73 months (range: 1.37–103.6 months). The 5-year disease-free survival (DFS) and overall survival (OS) rates of the 291 patients with TNBC were 72.51 and 82.47%, respectively. Higher levels of BCAT1 and CD133 expression independently indicated shorter DFS and OS. High levels of both BCAT1 and CD133 expression were detected in 36 (12.37%) patients, who had significantly shorter DFS and OS (both P < 0.001) compared to other patients. BCAT1 and CD133 can be considered as biomarkers with prognostic significance for TNBC.

中文翻译：

---

支链氨基酸转移酶1和CD133在三阴性乳腺癌中的预后意义。

先前的研究表明，支链氨基酸转移酶1（BCAT1）与三阴性乳腺癌（TNBC）的肿瘤进展有关。此外，CD133已经成为一种新型的肿瘤干细胞标记，用于指示肿瘤的进展。但是，这两个标志物的预后意义仍有待验证。本研究旨在探讨BCAT1和CD133表达与临床病理特征之间的相关性，以及TNBC患者的预后。该研究队列包括291名TNBC患者。构建了针对癌症和正常组织的组织微阵列。通过免疫组织化学染色检测BCAT1和CD133的表达，并使用H评分系统评估其水平。BCAT1和CD133表达的临界点使用接收器工作特性曲线确定。研究参与者的中位随访时间为68.73个月（范围：1.37–103.6个月）。291例TNBC患者的5年无病生存率（DFS）和总生存率（OS）分别为72.51和82.47％。BCAT1和CD133表达的较高水平独立表明较短的DFS和OS。在36名（12.37％）患者中检测到高水平的BCAT1和CD133表达，与其他患者相比，他们的DFS和OS显着缩短（均为P <0.001）。BCAT1和CD133可被认为是对TNBC具有预后意义的生物标志物。291例TNBC患者的5年无病生存率（DFS）和总生存率（OS）分别为72.51和82.47％。BCAT1和CD133表达的较高水平独立表明较短的DFS和OS。在36名（12.37％）患者中检测到高水平的BCAT1和CD133表达，与其他患者相比，他们的DFS和OS显着缩短（均为P <0.001）。BCAT1和CD133可被视为对TNBC具有预后意义的生物标志物。291例TNBC患者的5年无病生存率（DFS）和总生存率（OS）分别为72.51和82.47％。BCAT1和CD133表达的较高水平独立表明较短的DFS和OS。在36名（12.37％）患者中检测到高水平的BCAT1和CD133表达，与其他患者相比，他们的DFS和OS显着更短（均P <0.001）。BCAT1和CD133可被视为对TNBC具有预后意义的生物标志物。